Cited by 272Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic DiseasesPharmacology and Obesity Treatment

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index; none of the 85 sources its claims cite is checked for support yet.

Leptin at 14 y of age: an ongoing story

Open access
Friedman, Jeffrey M·2009·The American Journal of Clinical Nutrition

Abstract

The cloning of the ob gene and its gene product leptin has led to the elucidation of a robust physiologic system that maintains constancy of fat stores. Leptin is a peptide hormone secreted by adipose tissue and regulates adipose tissue mass and energy balance. Recessive mutations in the leptin gene are associated with massive obesity in mice and in some humans, which establishes a genetic basis for obesity. Leptin circulates in blood and acts on the brain to regulate food intake and energy expenditure. When fat mass decreases, plasma leptin concentrations decrease, which stimulates appetite and suppresses energy expenditure until fat mass is restored. When fat mass increases, leptin concentrations increase, which suppresses appetite until weight is lost. This system maintains homeostatic control of adipose tissue mass.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review summarizes 14 years of leptin research, describing leptin as an adipose-derived hormone in a negative feedback loop that regulates fat mass and energy balance, with leptin deficiency syndromes treatable by replacement. It argues that most obesity involves leptin resistance and that leptin provides a biological basis for obesity, while noting limited efficacy as monotherapy in unselected obese patients.

Key findings

  • Leptin circulates as an ~16-kD protein; concentrations rise and fall with adipose mass, and recombinant leptin reduces food intake and body weight in wild-type and ob mice but not db mice, establishing receptor specificity.
  • Leptin replacement improves leptin deficiency syndromes including congenital leptin deficiency, lipodystrophy, and hypothalamic amenorrhea; hypothalamic amenorrhea affects 4–8% of women of reproductive age and accounts for as many as 1 in 3 visits by women to an infertility clinic (personal communication).
  • Most obese patients are leptin resistant: in a small cohort, only ~1/3 showed clinically significant weight loss with leptin therapy, and ~10–15% of obese subjects have leptin concentrations indistinguishable from lean patients. Leptin plus amylin produced 12.9% weight loss, significantly greater than either agent alone.
  • Single-gene Mendelian defects account for ~8% or more of morbid human obesity, and twin studies indicate a heritability of 0.7–0.9 for obesity.

Methods

  • Narrative review/symposium article presented at “Leptin: Weight Management and Beyond,” Experimental Biology 2008; it synthesizes published animal and human literature.
  • No primary data collection, systematic search strategy, or formal quantitative analysis is described; the paper includes cited personal communications and references.

Limitations

  • No explicit limitations section is provided. Evident from the text: this is a non-systematic narrative review whose conclusions rely on selected studies and personal communications rather than a systematic search.
  • The paper states that it is yet unclear whether obese individuals who respond to leptin have lower starting leptin concentrations than nonresponders, and that the possibility of leptin efficacy in obese patients with low plasma leptin concentrations “has not been directly tested in humans.”
  • The molecular mechanism by which amylin ameliorates leptin resistance “has not been fully established.”

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3945/ajcn.2008.26788b

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 85 cited sources checked · 0 supported · 0 flagged

Show all 58 claims

  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 28
37 of 37
  • The paper relies on this without support.

    The majority of obese subjects are leptin resistant.

    “The majority of obese subjects are leptin resistant, which establishes that obesity is the result of hormone resistance.”
  • The paper relies on this without support.

    Leptin treatment results in weight loss in a subset of obese patients and can synergize with other antiobesity agents to reduce weight.

    “Leptin treatment results in weight loss in a subset of obese patients and can also synergize with other antiobesity agents to reduce weight.”
  • The paper relies on this without support.

    Diet-induced obesity in animals is a reliable predictor of leptin responses in humans.

    “often a reliable predictor of responses in humans”
  • The paper relies on this without support.

    Basic drives typically trump a conscious desire.

    “There are innumerable instances in our common experience suggesting that basic drives typically trump a conscious desire.”
4 of 4

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 73 references

Cited by

Sorted by citations

Items 201–271 of 271

Metadata

Authors
Friedman, J. M.
Affiliations
Howard Hughes Medical Institute (US)
Corresponding author
Friedman, Jeffrey M
Venue
The American Journal of Clinical Nutrition
Publisher
Elsevier BV
Published
2009-03
Volume
89
Issue
3
Pages
973S-979S
ISSN
0002-9165 (ISSN-L)
OpenAlex
W1966203604
Cited by
272
References
73
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 7 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 13 · 2016: 16 · 2015: 24 · 2014: 23 · 2013: 34 · 2012: 37
FWCI
3.82
Type
journal article
Language
en
Open access
Locations
  • American Journal of Clinical Nutrition (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Howard Hughes Medical Institute
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
leptin, leptin gene, obesity, adipose tissue, energy balance, appetite regulation, energy expenditure, dietary intake, adolescents, leptin receptor mutation
MeSH terms
Adipose Tissue, Animals, Body Weight, Cloning, Molecular, Humans, Leptin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review